Navigation Links
VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
Date:11/19/2010

BROOMFIELD, Colo., Nov. 19, 2010 /PRNewswire/ -- Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.  The intention of the biomarker analysis was to evaluate the ability of the blood-based test, VeriStrat, to predict patient outcomes with the erlotinib plus sorafenib combination regimen.

Forty-nine of 50 patients from the study had pretreatment serum samples available for analysis.  VeriStrat analysis classified 33 (67%) as likely to have "good" outcomes and 15 (31%) as likely to have "poor" outcomes.  Only one sample was classified as indeterminate.  VeriStrat Good patients had a significant improvement in overall survival compared with VeriStrat Poor patients (Hazard ratio= 0.30; CI: 0.12-0.74).  The median overall survival for VeriStrat Good patients was 13.7 months compared to 5.6 months for VeriStrat Poor patients. 

Researchers concluded that the proteomic test, VeriStrat, may identify a subset of patients that derive significant clinical benefit from first- line treatment of advanced NSCLC with dual targeted therapies.  Prospective studies are planned.

"This is the first study to demonstrate that a biomarker can identify patients who are likely to benefit from the erlotinib plus sorafenib combination," stated Egbert Smit, MD, PhD.  "This is exciting for lung cancer patients as the all-oral combination may be more tolerable than traditional platinum-based regimens, with similar efficacy.  More research is needed to fully define the role of this biomarker and identify the specific groups of patients that this combination may benefit."

About NSCLC:  As reporte
'/>"/>

SOURCE Biodesix
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory
2. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
3. Research Identifies Need for Improved Understanding of Sickle Cell Disease in Adulthood
4. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
5. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
6. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
7. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
8. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Nemours Center for Childhood Cancer Research Team at the Alfred I. duPont Hospital for Children Identifies the Function of a Biomarker Present in Prostate Cancer Cells: New Insight into Therapeutic Benefit for Patients with Advanced Prostate Cancer
11. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe ... Italy , UK, Spain ) Summary GBI ... Europe ( Germany , France , ... analysis of the transcatheter heart valves market in Europe . ... period and key company share data by revenue in 2013 for the following ...
(Date:9/23/2014)... -- Report Details Where is the prostate cancer ... potential revenues to 2024, assessing data, trends, opportunities and ... charts, and graphs. Our new study lets you assess ... market, showing their prospects to 2024. Discover the most ... prospects. Our new study lets you assess forecasted sales ...
(Date:9/23/2014)... , Sept. 23, 2014  SI-BONE, Inc., a medical ... Implant System, ® a minimally invasive surgical (MIS) ... today announced that the U.S. Patent and Trademark Office ... and methods for the fixation and fusion of bone.  ... implant with a tapered distal end that may be placed from one ...
Breaking Medicine Technology:Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain) 2The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 2The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 3The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 4The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 5SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3
... a biotechnology company that develops targeted therapies for oncology ... results from studies of TRC105 and TRC102 in patients ... Society of Clinical Oncology annual meeting this May 28th ... pathways with the potential for broad application to a ...
... Confirm Tapentadol Efficacy and Tolerability for Acute Pain PatientsRARITAN, ... to 30 percent of all people who have surgery ... The use of opioid pain medicines during and after ... side effects. Nausea and vomiting are uncomfortable and bothersome ...
Cached Medicine Technology:TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 3New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 4New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 5New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 6New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 7New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 8
(Date:9/23/2014)... Kathleen Doheny HealthDay ... For babies born at very low birth weights, breast milk ... a potentially dangerous infection known as cytomegalovirus (CMV), a new ... low birth weight infants -- all of whom weighed 3.3 ... with a history of CMV infection, to see whether breast ...
(Date:9/23/2014)... News) -- A test used to diagnose lung cancer may ... infections are more common, a new analysis says. ... use of what,s known as functional imaging. For lung cancer, ... according to the study authors. Cancerous tumors generally look ... the lungs that don,t have cancer, according to background information ...
(Date:9/23/2014)... Genomic medicine is rapidly developing, bringing with its ... and optimize prevention and treatment interventions. Genetic ... immunodeficiency virus (HIV) and hepatitis c virus (HPC), ... be used to screen for an individual,s susceptibility ... treatments for addiction. , While there appear to ...
(Date:9/23/2014)... 2014 What information do patients ... Quality Forum (NQF) released a report ( http://bit.ly/1DwekE9 ... an infographic ( http://bit.ly/1tX3lzA ) resulting from an ... how patients define affordability, and what information and ... best possible healthcare at the lowest possible cost. ...
(Date:9/23/2014)... New York, NY (PRWEB) September 23, 2014 ... progressive congregation on Manhattan’s Upper West Side that ... will host Inhabiting Eden: Christians, Scripture and the ... K. Tull, A. B. Rhodes Professor Emerita of ... explore the Bible for ancient wisdom that lends ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2
... month long fund raising events to find the cure, ... officially declared November as Tay-Sachs Awareness Month,and encourages all ... the need for research to help find a cure. ... frequently in Ashkenazi Jews, French,Canadians, Louisiana Cajuns, and Irish ...
... breakdown, in the epidermis , , FRIDAY, Nov. 2 (Health ... the biological mechanism by which stress increases susceptibility to ... the basis of the stress," said study author Dr. ... of California, San Francisco, and the VA Medical Center, ...
... Mammography Van Features ... NovationDR Digital System, MALVERN, Pa., Nov. 2 ... digital mammography,system in the U.S. The MAMMOMAT(R) NovationDR, a ... Nevada Cancer Institute,s,(NVCI) new Hope Coach, a mobile digital ...
... Emotional Intelligence could be defined as the capacity to perceive, ... so as to be able to distinguish between emotions and ... actions. One of the important benefits of developing this type ... with others and to face an ever changing social and ...
... LAUREL, N.J., Nov. 2 MedQuist Inc. (Pink,Sheets: MEDQ) ... its,previously-disclosed review of strategic alternatives for the Company, is,evaluating ... best interests of the,Company and its shareholders, in light ... ("Philips") of its decision to proceed,with the sale of ...
... Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today ... designation awarded to PI-88 for the,prevention of tumour ... in order to commence the Phase 3 program ... continue with the Special Protocol,Assessment process. The ...
Cached Medicine News:Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 2Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 3Health News:Stress Robs Skin of Antimicrobial Defenses 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 3Health News:Emotional Intelligence and the use of tobacco and cannabis 2Health News:MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: